Home › Companies › Crescent Biopharma, Inc.

Crescent Biopharma, Inc. (CBIO) proxy voting records

How asset managers voted at Crescent Biopharma, Inc.’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

• TickerCBIO
• CUSIP issuer number38000Q, G2545C
• SEC CIK1253689

Not to be confused with Crescent Energy Company (company); Crescent Point Energy Corp. (company).

Recent shareholder votes

• June 2, 2026 annual meeting (2025-2026 proxy season): 4 items in Crescent Biopharma, Inc.'s official results (Form 8-K, filed June 3, 2026); lowest support 98% of votes cast (Approval, on a non-binding advisory basis, of the compensation…). Full results and how funds voted.
• May 1, 2024 annual meeting (2023-2024 proxy season): 6 items in Crescent Biopharma, Inc.'s official results (Form 8-K, filed May 2, 2024); lowest support 93% of votes cast (Elect Director: Daniel Junius). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Earlier seasons list this company under the name GLYCOMIMETICS INC., as its holders filed it.

Explore Crescent Biopharma, Inc. in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. Ticker as listed by the SEC on November 6, 2026. This page is rebuilt weekly; built November 9, 2026.